Novartis Ups Sale Guidance And Heralds Rejuvenated Pipeline

CEO Vas Narasimhan has highlighted the strong momentum from six new products plus the old favorites Entresto and Cosentyx, saying that there are over 30 high-value medicines in the pipeline that will drive continued mid-single digit sales growth beyond 2029.

Novartis

More from Deals

More from R&D